by | Jan 8, 2025 | Publications
Ann Hematol. 2024 Dec;103(12):5849-5859. doi: 10.1007/s00277-024-06129-5. Epub 2024 Dec 7. ABSTRACT Patient-reported outcomes (PROs) are crucial endpoints in multiple myeloma (MM) randomized controlled trials (RCTs), yet there is significant variability in their...
by | Jan 7, 2025 | Publications
Clin Lymphoma Myeloma Leuk. 2025 Jan;25(1):32-44. doi: 10.1016/j.clml.2024.09.008. Epub 2024 Sep 21. ABSTRACT BACKGROUND: The efficacy of elotuzumab, an anti-SLAMF7 monoclonal antibody, in treating relapsed/refractory multiple myeloma (RRMM) and newly-diagnosed...
by | Jan 7, 2025 | Publications
Front Immunol. 2024 Dec 23;15:1466443. doi: 10.3389/fimmu.2024.1466443. eCollection 2024. ABSTRACT BACKGROUND: Clinical studies have demonstrated the high efficacy of using chimeric antigen receptor (CAR)-T cells targeting B-cell maturation antigen (BCMA) and orphan G...
by | Dec 28, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2024 Dec 6:S2152-2650(24)02444-3. doi: 10.1016/j.clml.2024.12.006. Online ahead of print. ABSTRACT Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant condition of multiple myeloma (MM). Evidence suggested old age,...
by | Nov 23, 2024 | Publications
J Oncol Pharm Pract. 2024 Nov 21:10781552241290452. doi: 10.1177/10781552241290452. Online ahead of print. ABSTRACT INTRODUCTION: Several meta-analyses (MAs) of the efficacy and safety of daratumumab in refractory/relapsed multiple myeloma (RRMM) exist. They include...
by | Nov 18, 2024 | Publications
Heliyon. 2024 Oct 22;10(21):e39698. doi: 10.1016/j.heliyon.2024.e39698. eCollection 2024 Nov 15. ABSTRACT Multiple myeloma (MM) accounts for almost 15 % of all neoplastic malignancies around the globe. This systematic review intends to analyse data on the treatment...